FMA
BPMC

FNY Managed Accounts’s Blueprint Medicines BPMC Stock Holding History

FNY Managed Accounts’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50
Closed -$3K – 623
2017
Q4 		$3K Buy
+50
New +$3.52K ﹤0.01% 385

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

FNY Managed Accounts's BPMC Position: Q1 2018 in Review

FNY Managed Accounts sold out of Blueprint Medicines (BPMC) in Q1 2018, closing a stake of 50 shares — an estimated $3K sold.

FNY Managed Accounts first reported a position in BPMC in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 175 funds tracked by Wall St. Rank hold BPMC as of Q1 2018.

  • FNY Managed Accounts reported no remaining Blueprint Medicines position as of Q1 2018 after selling out during the quarter.
  • FNY Managed Accounts sold 50 Blueprint Medicines shares in Q1 2018, an estimated $3K.
  • FNY Managed Accounts first reported a position in Blueprint Medicines in Q4 2017 and held it in 1 quarter.
  • FNY Managed Accounts's Blueprint Medicines position peaked at $3K in Q4 2017.
  • 175 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.